<DOC>
	<DOC>NCT00044408</DOC>
	<brief_summary>The purpose of this protocol is to determine if an investigational drug known as LY333531 is effective in treating nerve malfunction in diabetes.</brief_summary>
	<brief_title>Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Ruboxistaurin</mesh_term>
	<criteria>Patients must have type I or type II Diabetes Mellitus. Have clinically diagnosed positive sensory symptoms such as numbness, lancinating pain, burning pain, aching pain, allodynia and prickling sensation that have been present not greater than 5 years but stable for 6 months. Has a HbA1C less than or equal to 12%. Patients with HbA1C greater than 9% must be insulin therapy. Must be 18 years or older. Be able to visit the doctor's office approximately 3 times over a maximum of a 6week period to determine if you can continue in the study. History of significant liver problems. Have poor kidney function. Drink an excess of alcohol or abuse drugs. Have recently participated or currently participating in a Medical study in which you receive an experimental drug. Are a woman and are pregnant or breastfeeding, intend to become pregnant within the next 2 years or a woman not using effective birth control.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>